Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27822866 | 0.77 | DRD2 (0.37) | KDM5ATRPC6KMT2A | |
| SCHEMBL2517603 | 0.74 | RIPK1 (0.51) | TLR9TLR8TLR7RIPK1PKM | |
| SCHEMBL15070484 | 0.73 | RIPK1 (0.50) | RIPK1PKMTRPC6KMT2APOLB | |
| SCHEMBL28471941 | 0.71 | RIPK1 (0.48) | TLR9TLR8TLR7RIPK1PKM | |
| SCHEMBL2722252 | 0.71 | POLB (0.48) | TLR9TLR8TLR7RIPK1PARP1 | |
| SCHEMBL3329035 | 0.70 | KDM4E (0.50) | RIPK1PARP1PKMKMT2APOLB | |
| SCHEMBL1493280 | 0.70 | HTT (0.54) | KMT2A | |
| SCHEMBL13532859 | 0.70 | KDM4E (0.46) | RIPK1PARP1PKMKMT2APOLB | |
| SCHEMBL27971608 | 0.69 | PKM (0.49) | RIPK1PKMKMT2APOLBNAMPT | |
| SCHEMBL170833 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180237421-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237421-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINE1 | TLR9 4654/4885TLR8 3619/4885TLR7 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.